Get the Stockscreener App
66.70
0.36%
-0.2814
Cytokinetics Inc stock is traded at $66.70, with a volume of 205.74K.
It is down -0.36% in the last 24 hours and up +6.65% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$66.98
Open:
$66.61
24h Volume:
205.74K
Relative Volume:
0.11
Market Cap:
$8.15B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-12.68
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
+2.62%
1M Performance:
+6.65%
6M Performance:
+76.38%
1Y Performance:
+43.84%
1-Day Range:
$65.54
$67.03
1-Week Range:
$64.58
$67.67
52-Week Range:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
66.69 | 8.19B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.90 | 119.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.96 | 83.75B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
841.64 | 52.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
333.69 | 44.12B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
357.43 | 39.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Skandinaviska Enskilda Banken AB publ Boosts Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo - Yahoo Finance
Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth - Finviz
Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline - Finviz
Cytokinetics wins EC nod for Myqorzo - The Pharma Letter
Cytokinetics Reports EC Approval of Myqorzo for Obstructive Hypertrophic Cardiomyopathy - marketscreener.com
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - The Manila Times
Cytokinetics Receives European Commission Approval for MYQORZO® (aficamten) to Treat Obstructive Hypertrophic Cardiomyopathy; Launch Planned in Germany for Q2 2026 - Quiver Quantitative
Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock Analysis: A 35.74% Potential Upside Fuels Investor Interest - DirectorsTalk Interviews
Does Cytokinetics Incorporated offer margin of safetyJuly 2025 Price Swings & Daily Growth Stock Investment Tips - mfd.ru
CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup - ChartMill
Will Cytokinetics Incorporated stock outperform Nasdaq index2025 Macro Impact & AI Driven Price Forecasts - mfd.ru
Cytokinetics (CYTK) Valuation Check After MYQORZO Approval And Renewed Analyst Bullishness - Yahoo Finance
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 - Bitget
Cytokinetics (CYTK) Is Up 5.2% After Aficamten Milestones And Probe News Has The Bull Case Changed? - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ: CYTK) Long Term Investor Alert: Investigation of potential Wrongdoing - openPR.com
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Boston Scientific (BSX) - The Globe and Mail
Cytokinetics announces recipients of its eighth annual communications grant program - marketscreener.com
Cytokinetics Announces Recipients Of Its Eighth Annual Communications Grant Program - TradingView
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program - The Manila Times
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aug Selloffs: Is Cytokinetics Incorporated a potential multi baggerJuly 2025 Setups & Weekly High Potential Alerts - baoquankhu1.vn
Bank Watch: Does Cytokinetics Incorporated offer margin of safetyJuly 2025 Momentum & Stepwise Trade Signal Implementation - baoquankhu1.vn
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Andrew Callos Sells 15,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Bank of America Securities Remains a Hold on Cytokinetics (CYTK) - The Globe and Mail
Surprises Report: Is Cytokinetics Incorporated stock a good pick for beginners2025 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
Cytokinetics stock maintains Buy rating at B.Riley amid strong CMI market - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
Cytokinetics, Incorporated (CYTK): A Bull Case Theory - Finviz
Truist Financial Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Truist Raises Price Target on Cytokinetics to $92 From $84, Keeps Buy Rating - marketscreener.com
Truist Securities Raises Price Target for CYTK with Buy Rating | - GuruFocus
2026 Biotech Hot Picks: Top 7 Stocks to Watch | Truist Analysis - techi.com
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Play with a 41.55% Upside Potential - DirectorsTalk Interviews
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 886 Shares - MarketBeat
New Highs: Whats the RSI of Cytokinetics Incorporated stockQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Lisanti Capital Growth LLC Acquires New Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Sells 444,464 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Will Cytokinetics Incorporated outperform its industry peersShort Setup & Stock Portfolio Risk Management - mfd.ru
J. Safra Sarasin Holding AG Sells 43,723 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cardiac Myosin Inhibitor Now Available for Treating Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Diagnostic and Interventional Cardiology
Halozyme buys a biotech startup; Cytokinetics launches heart drug - BioPharma Dive
Cytokinetics (CYTK) Receives Overweight Rating from Barclays, PT Set at $87 | CYTK Stock News - GuruFocus
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Barclays - MarketBeat
Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM - Yahoo Finance
CYTK: Cytokinetics Launches Myqorzo in the U.S. for Heart Condition - GuruFocus
Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum - Yahoo Finance
How MYQORZO’s REMS‑Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):